Zoetis Inc (ZTS) was Downgraded by Goldman to ” Sell”. Earlier the firm had a rating of “Neutral ” on the company shares. Goldman advised their investors in a research report released on May 6, 2016.
On the company’s financial health, Zoetis Inc reported $0.48 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on May 4, 2016. Analyst had a consensus of $0.41. The company had revenue of $1162.00 million for the quarter, compared to analysts expectations of $1103.71 million. The company’s revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.41 EPS.
Zoetis Inc closed down -1.1 points or -2.28% at $47.05 with 54,30,442 shares getting traded on Wednesday. Post opening the session at $47.91, the shares hit an intraday low of $46.05 and an intraday high of $48.04 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Zoetis Inc. is engaged in the discovery development manufacture and commercialization of animal health medicines and vaccines with a focus on both livestock and companion animals. The Company markets products across four regions: the United States Europe/Africa/Middle East Canada/Latin America and Asia/Pacific; eight species: the livestock species of cattle swine poultry sheep and fish and the companion animal species of dogs cats and horses and five product categories: anti-infectives vaccines parasiticides medicated feed additives and other pharmaceutical products. In addition its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.